Login to Your Account

Short Of SPA's 10 Percent Bar

Medarex: Ipilimumab Misses Endpoint In Melanoma Study

By Randall Osborne

Wednesday, December 12, 2007
No Abstract

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription